Thu, 09 Oct 2008 13:38:28 -0400 PeerView CME/CE Audio Podcast - Hematology PeerView Press http://www.peerviewpress.com Podcast Maker v1.3.3 - http://www.lemonzdream.com/podcastmaker PeerView Press is an independent, professional medical publishing concern focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerView Publications, PeerView Press is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes. Thought leader perspectives on current clinical advances in medicine PeerView Press is an independent, professional medical publishing concern focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerView Publications, PeerView Press is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes. 2007 PeerView Press, 24 West 40th Street, Suite 950, New York, NY 10018 webmaster@peerviewpress.com http://podcast.peerviewpress.com/haematology/hematology_audio_podcast_album_art_QAAppr_160307_144.jpg PeerView CME/CE Audio Podcast - Hematology http://www.peerviewpress.com 144 144 Science & Medicine CME, Medical Education, continuing medical education, CME credits, PeerView Press, inSession, inReview, CE, Haematology no Rafael Fonseca, MD - Assessing Modern MM Tx: From Novel Induction Strategies to Modified Regimens in Relapsed/Refractory Disease PeerView Press In this activity, a leading hematologist-oncologist discusses the integration of novel regimens in the clinical spectrum of treatment for patients with multiple myeloma. After a brief review of standard induction therapies for patients undergoing stem-cell transplant, the discussion will move on to review updated safety and efficacy data on regimens that contain immunomodulating therapies or proteasome inhibitors. Other topics of discussion in upfront settings will include the feasibility of prolonged front-line therapy, stem cell collection, early treatment, and maintenance therapy. The activity will conclude with a discussion of treatment in relapsed/refractory myeloma, including an evaluation of both established and emerging agents. Please be sure to view the accompanying (PDF) file for full CME/CE information. In this activity, a leading hematologist-oncologist discusses the integration of novel regimens in the clinical spectrum of treatment for patients with multiple myeloma. After a brief review of standard induction therapies for patients undergoing stem-cell transplant, the discussion will move on to review updated safety and efficacy data on regimens that contain immunomodulating therapies or proteasome inhibitors. Other topics of discussion in upfront settings will include the feasibility of prolonged front-line therapy, stem cell collection, early treatment, and maintenance therapy. The activity will conclude with a discussion of treatment in relapsed/refractory myeloma, including an evaluation of both established and emerging agents. http://podcast.peerviewpress.com/haematology/PA05171FCn198.mp3 http://podcast.peerviewpress.com/haematology/PA05171FCn198.mp3 Mon, 29 Sep 2008 16:41:06 -0400 Science & Medicine no 00:23:06 multiple myeloma, relapsed, refractory, induction, upfront, Thal-Dex, bortezomib, IMiD, stem cell CME/CE Information - Assessing Modern MM Tx: From Novel Induction Strategies to Modified Regimens in Relapsed/Refractory Disease PeerView Press Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file. http://podcast.peerviewpress.com/haematology/PA05171FCCMEinfo.pdf http://podcast.peerviewpress.com/haematology/PA05171FCCMEinfo.pdf Mon, 29 Sep 2008 16:41:01 -0400 Science & Medicine no 00:00:00 multiple myeloma, relapsed, refractory, induction, upfront, Thal-Dex, bortezomib, IMiD, stem cell William Bensinger, MD - Therapeutic Options for Transplant- and Non-Transplant-Eligible Patients With Multiple Myeloma: A Clinical Update PeerView Press In this activity, experts in hematology discuss latest clinical advances in the treatment of multiple myeloma. Please be sure to view the accompanying (PDF) file for full CME/CE information. In this activity, experts in hematology discuss latest clinical advances in the treatment of multiple myeloma. http://podcast.peerviewpress.com/haematology/PA04421FCr392.mp3 http://podcast.peerviewpress.com/haematology/PA04421FCr392.mp3 Thu, 04 Sep 2008 16:35:29 -0400 Science & Medicine no 00:44:52 Multiple myeloma, melphalan, alkylators, thalidomide, bortezomib, lenalidomide, dexamethasone, thrombosis, proteasome inhibitor, carfilzomib CME/CE Information - Therapeutic Options for Transplant- and Non-Transplant-Eligible Patients With Multiple Myeloma: A Clinical Update PeerView Press Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file. http://podcast.peerviewpress.com/haematology/PA04421FCCMEinfo.pdf http://podcast.peerviewpress.com/haematology/PA04421FCCMEInfo.pdf Thu, 04 Sep 2008 16:35:29 -0400 Science & Medicine no 00:00:00 Multiple myeloma, melphalan, alkylators, thalidomide, bortezomib, lenalidomide, dexamethasone, thrombosis, proteasome inhibitor, carfilzomib Frederick R. Rickles, MD, FACP - Effective Prevention and Management of Venous Thromboembolism in Patients With Cancer PeerView Press In this CME activity, an expert in the management of venous thromboembolism (VTE) presents recent data on therapies used to treat this condition, focusing on patients with malignancies. The different guidelines for management of this condition will be briefly reviewed. Diagnosis of this condition is also highlighted. Please be sure to view the accompanying (PDF) file or full CME/CE information. In this CME activity, an expert in the management of venous thromboembolism (VTE) presents recent data on therapies used to treat this condition, focusing on patients with malignancies. The different guidelines for management of this condition will be briefly reviewed. Diagnosis of this condition is also highlighted. http://podcast.peerviewpress.com/haematology/PA04763FCn185.mp3 http://podcast.peerviewpress.com/haematology/PA04763FCn185.mp3 Wed, 03 Sep 2008 14:24:11 -0400 Science & Medicine no 00:33:17 VTE, cancer, PE, thrombosis, bleeding, DVT, NCCN, unfractionated heparin, warfarin, LMWH, VKA CME/CE Information - Effective Prevention and Management of Venous Thromboembolism in Patients With Cancer PeerView Press Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file. http://podcast.peerviewpress.com/haematology/PA04763FCCMEinfo.pdf http://podcast.peerviewpress.com/haematology/PA04763FCCMEinfo.pdf Wed, 03 Sep 2008 14:24:09 -0400 Science & Medicine no 00:00:00 VTE, cancer, PE, thrombosis, bleeding, DVT, NCCN, unfractionated heparin, warfarin, LMWH, VKA Moshe Talpaz, MD - Controversial Issues in Chronic Myelogenous Leukemia: Debating the Use of Molecular Monitoring and Potential for Individualized Therapy PeerView Press In this CME activity, experts provide an update on treatment resistance in CML. Definitions, prevalence, and mechanisms of resistance are reviewed, the benefits and limitations of using molecular monitoring in the clinical management of CML are assessed, strategies for selecting optimal targeted therapy to circumvent or overcome treatment resistance are debated, and the potential for tailoring tyrosine kinase therapy according to individual patient or disease characteristics, including BCR-ABL mutations, is discussed. Please be sure to view the accompanying (PDF) file or full CME/CE information. In this CME activity, experts provide an update on treatment resistance in CML. Definitions, prevalence, and mechanisms of resistance are reviewed, the benefits and limitations of using molecular monitoring in the clinical management of CML are assessed, strategies for selecting optimal targeted therapy to circumvent or overcome treatment resistance are debated, and the potential for tailoring tyrosine kinase therapy according to individual patient or disease characteristics, including BCR-ABL mutations, is discussed. http://podcast.peerviewpress.com/haematology/PA04328FCe015.mp3 http://podcast.peerviewpress.com/haematology/PA04328FCe015.mp3 Thu, 17 Jul 2008 09:35:24 -0400 Science & Medicine no 00:40:15 CML, chronic myelogenous leukemia, BCR-ABL, molecular monitoring, imatinib, dasatinib, resistance, TKI CME/CE Information - Controversial Issues in Chronic Myelogenous Leukemia: Debating the Use of Molecular Monitoring and Potential for Individualized Therapy PeerView Press Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file. http://podcast.peerviewpress.com/haematology/PA04328FCCMEinfo.pdf http://podcast.peerviewpress.com/haematology/PA04328FCCMEinfo.pdf Thu, 17 Jul 2008 09:34:24 -0400 Science & Medicine no 00:00:00 CML, chronic myelogenous leukemia, BCR-ABL, molecular monitoring, imatinib, dasatinib, resistance, TKI Guillermo Garcia-Manero, MD - Epigenetic Alterations as Targets of Therapy in Myelodysplastic Syndromes: Applying Science to Clinical Practice PeerView Press In this program, an expert will discuss the concept of epigenetics and targets of epigenetic therapy in myelodysplastic syndromes (MDS). Recent data on efficacy and safety of novel DNA hypomethylating agents in the treatment of MDS are also reviewed, as well as the implications of these data for clinical practice and research. Please be sure to view the accompanying (PDF) file or full CME/CE information. In this program, an expert will discuss the concept of epigenetics and targets of epigenetic therapy in myelodysplastic syndromes (MDS). Recent data on efficacy and safety of novel DNA hypomethylating agents in the treatment of MDS are also reviewed, as well as the implications of these data for clinical practice and research. http://podcast.peerviewpress.com/haematology/PA04356FCr372.mp3 http://podcast.peerviewpress.com/haematology/PA04356FCr372.mp3 Mon, 12 May 2008 14:31:22 -0400 Science & Medicine no 00:33:15 Epigenetics, DNA hypomethylating agents, 5-azacitidine, decitabine, growth-factor support, dosing regimens, combination regimens, toxicity, myelosuppression, thrombocytopenia, neutropenia CME/CE Info - Epigenetic Alterations as Targets of Therapy in Myelodysplastic Syndromes: Applying Science to Clinical Practice PeerView Press Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file. http://podcast.peerviewpress.com/haematology/PA04356FCCMEinfo.pdf http://podcast.peerviewpress.com/haematology/PA04356FCCMEinfo.pdf Mon, 12 May 2008 14:30:24 -0400 Science & Medicine no 00:00:00 Epigenetics, DNA hypomethylating agents, 5-azacitidine, decitabine, growth-factor support, dosing regimens, combination regimens, toxicity, myelosuppression, thrombocytopenia, neutropenia Jean-Pierre Issa, MD - New Classification Systems and Therapies Instigate Evolving Diagnostic and Treatment Models of MDS PeerView Press In this activity, an expert in hematology discusses clinical issues and latest evidence of diagnosis and treatment of MDS. Please be sure to view the accompanying (PDF) file or full CME/CE information. In this activity, an expert in hematology discusses clinical issues and latest evidence of diagnosis and treatment of MDS. http://podcast.peerviewpress.com/haematology/PA04357FCn175.mp3 http://podcast.peerviewpress.com/haematology/PA04357FCn175.mp3 Mon, 24 Mar 2008 16:33:33 -0400 Science & Medicine no 00:52:43 CME, Medical Education, continuing medical education, CME credits, PeerView Press, inSession, inReview, CE, Haematology CME/CE Info - New Classification Systems and Therapies Instigate Evolving Diagnostic and Treatment Models of MDS PeerView Press Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file. http://podcast.peerviewpress.com/haematology/PA04357FCCMEinfo.pdf http://podcast.peerviewpress.com/haematology/PA04357FCCMEinfo.pdf Mon, 24 Mar 2008 16:33:30 -0400 Science & Medicine no 00:00:00 CME, Medical Education, continuing medical education, CME credits, PeerView Press, inSession, inReview, CE, Haematology Jamile M. Shammo, MD, FASCP - State of the Science in MDS: Update on Diagnosis, Evaluation, and Treatment PeerView Press In this program, MDS experts present an update on disease classification and review new data on current and emerging treatment options. Please be sure to view the accompanying (PDF) file or full CME/CE information. In this program, MDS experts present an update on disease classification and review new data on current and emerging treatment options. http://podcast.peerviewpress.com/haematology/PA04297FCr364.mp3 http://podcast.peerviewpress.com/haematology/PA04297FCr364.mp3 Thu, 28 Feb 2008 16:31:07 -0500 Science & Medicine no 00:37:22 acute myeloid leukemia, AMG 531, AML, American Society of Hematology, anemia, ASH, azacitidine, clofarabine, cytarabine, cytogenetic testing, decitabine, deferasirox, deletion 5q, etanercept, FAB classification, homoharringtonine, IPSS, iron chelation CME/CE Information - State of the Science in MDS: Update on Diagnosis, Evaluation, and Treatment PeerView Press Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file. http://podcast.peerviewpress.com/haematology/PA04297FCCMEinfo.pdf http://podcast.peerviewpress.com/haematology/PA04297FCCMEinfo.pdf Thu, 28 Feb 2008 16:31:04 -0500 Science & Medicine no 00:00:00 acute myeloid leukemia, AMG 531, AML, American Society of Hematology, anemia, ASH, azacitidine, clofarabine, cytarabine, cytogenetic testing, decitabine, deferasirox, deletion 5q, etanercept, FAB classification, homoharringtonine, IPSS, iron chelation Aryeh Shander, MD - Anemia Management and Blood Conservation in the Hospital Setting PeerView Press In this activity, physicians who are expert in the management of anemia and the use of blood products discuss the efficacy and risks of RBC transfusion and alternative strategies for the management of anemia in the critically ill, including the use of erythropoiesis-stimulating agents. Please be sure to view the accompanying (PDF) file or full CME/CE information. In this activity, physicians who are expert in the management of anemia and the use of blood products discuss the efficacy and risks of RBC transfusion and alternative strategies for the management of anemia in the critically ill, including the use of erythropoiesis-stimulating agents. http://podcast.peerviewpress.com/haematology/PA03696FCr324.mp3 http://podcast.peerviewpress.com/haematology/PA03696FCr324.mp3 Tue, 24 Jul 2007 10:35:13 -0400 Science & Medicine no 00:36:59 Anemia, Blood conservation, Critical care, Erythropoietin, Transfusion CME/CE Information - Anemia Management and Blood Conservation in the Hospital Setting PeerView Press Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file. http://podcast.peerviewpress.com/haematology/PA03696FCCMEinfo.pdf http://podcast.peerviewpress.com/haematology/PA03696FCCMEinfo.pdf Tue, 24 Jul 2007 10:34:50 -0400 Science & Medicine no 00:00:00 Anemia, Blood conservation, Critical care, Erythropoietin, Transfusion Jamile M. Shammo, MD, FASCP - Advances in Management of Myelodysplastic Syndrome PeerView Press In this CME activity, experts in the treatment of MDS present recent data on the efficacy and safety of novel agents used in the treatment of MDS. The current treatment options are also highlighted. Please be sure to view the accompanying (PDF) file or full CME/CE information. In this CME activity, experts in the treatment of MDS present recent data on the efficacy and safety of novel agents used in the treatment of MDS. The current treatment options are also highlighted. http://podcast.peerviewpress.com/haematology/PA3729FCs339.mp3 http://podcast.peerviewpress.com/haematology/PA3729FCs339.mp3 Mon, 19 Mar 2007 10:39:29 -0400 Science & Medicine no 00:31:28 MDS, myelodysplastic syndromes, AML, HSCT, allogeneic stem cell transplantation, GVHD, graft-versus-host disease, 5-azacytidine, decitabine, lenalidomide, iron chelation therapies, gemtuzumab ozogamicin, tipifarnib, clofarabine, lonafarnib, valproic acid CME/CE Information - Advances in Management of Myelodysplastic Syndrome PeerView Press Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file. http://podcast.peerviewpress.com/haematology/PA03729FCCMEinfo.pdf http://podcast.peerviewpress.com/haematology/PA03729FCCMEinfo.pdf Mon, 19 Mar 2007 10:39:24 -0400 Science & Medicine no 00:00:00 CME, Medical Education, continuing medical education, CME credits, PeerView Press, inSession, inReview, CE, Haematology